Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Mercury immune toxicity in harbour seals: links to in vitro toxicity.

  PMID 18959786 · PMC2600635 · Environmental health : a global access science source · 2008 · 8 claims · 6 setups

  Full-text index only

  In vitro MeHg exposure reduces seal lymphocyte number, viability, metabolic activity, and DNA/RNA synthesis

  blood pha-stimulated cytoplasmic cold trypan mts

• Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.

  PMID 37217248 · PMC10231005 · Journal for immunotherapy of cancer · 2023 · 8 claims · 8 setups

  Has reproduction · 76

  High expression of IFN-I signaling/response genes (IFNAR1, IFNAR2, STAT1, MX1, OAS1) predicts favorable relapse-free survival in B-ALL patients

  cog b-all eμ-myc crispra gene-expression-based flow mass

• Immune profiling in a living human recipient of a gene-edited pig kidney.

  PMID 41507576 · PMC12823403 · Nature medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  Xenograft experienced early T cell-mediated rejection (Banff grade 2A) within 1 week post-transplant despite profound circulating T cell depletion, likely driven by subtherapeutic immunosuppression and residual CD8+ T cells in lymph nodes.

  xenotransplant recipient kidney integrative single-cell flow

• A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2.

  PMID 41876554 · PMC13172340 · NPJ vaccines · 2026 · 8 claims · 8 setups

  Full-text index only

  The G1-C mRNA vaccine (RBD + membrane protein epitope) induces 8.2-fold higher WA1 RBD-specific IgG and 16.6-fold higher XBB.1.5 RBD-specific IgG than the RBD-only vaccine

  plasma pbmcs spleen bone elisa pseudovirus intracellular

• Identification and characterization of HLA-A*0301 epitopes in HIV-1 gag proteins using a novel approach.

  PMID 19903485 · PMC2836169 · Journal of immunological methods · 2010 · 7 claims · 7 setups

  Full-text index only

  PS mutations V7I and I34L (p17) and K403R (p7) in HIV-1 gag significantly correlate with HLA-A*0301

  hiv-1-infected genomic hiv-1 hla-a*0301 statistical pcr gag

• Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

  PMID 41325133 · PMC13037771 · Cancer research communications · 2026 · 7 claims · 4 setups

  Full-text index only

  A palbociclib lead-in prior to retifanlimab produced a high rate of immune-related adverse events, leading to halted enrollment.

  tumor peripheral patients single-cell high-parameter clinical

• Depletion of HIV reservoir by activation of ISR signaling in resting CD4(+)T cells.

  PMID 36590168 · PMC9800255 · iScience · 2023 · 8 claims · 8 setups

  Has reproduction · 89

  Activation of ISR/ATF4 signaling (via HA15) reverses HIV latency in Jurkat models of HIV latency (J-Lat A1, 2D10)

  jurkat cd4+ hiv-negative resting flow trypan western

• Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

  PMID 17595663 · PMC2360307 · British journal of cancer · 2007 · 8 claims · 14 setups

  Full-text index only

  A SNP in the cytidine deaminase (CDA) gene (208G>A, haplotype *3) decreases gemcitabine clearance, increases Cmax/AUC, and increases neutropenia risk when gemcitabine is combined with platinum drugs or 5-FU

  japanese paraffin-embedded tumour recombinant prospective immunohistochemistry pcr

• Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

  PMID 41540108 · PMC13004696 · Nature medicine · 2026 · 7 claims · 7 setups

  Full-text index only

  GPRC5D antigenic drift/mutational events occurred in 68.4% of relapsed cases following anti-GPRC5D TCE therapy (13/19 evaluable patients)

  cd138+ pbmcs cohort bulk single-cell targeted